Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nat Biotechnol. Author manuscript; available in PMC Feb 1, 2012.
Published in final edited form as:
PMCID: PMC3152587
NIHMSID: NIHMS307793

Genetic engineering of human ES and iPS cells using TALE nucleases

Abstract

Targeted genetic engineering of human pluripotent cells is a prerequisite for exploiting their full potential. Such genetic manipulations can be achieved using site-specific nucleases. Here, we engineered Transcription Activation-Like Effector Nucleases (TALENs) for five distinct genomic loci. At all loci tested we obtained hESC and iPSC single-cell-derived clones carrying transgenic cassettes solely at the TALEN-specified location. Thus, TALENs mediate site-specific genome modifications in human pluripotent cells with comparable efficiency and precision as zinc finger nucleases (ZFNs).

Gene targeting of human pluripotent cells by homologous recombination is inefficient, which has impeded the use of human ES and iPS cells (hESCs and hiPSCs) in disease models. To overcome this limitation, we and others have shown that zinc finger nucleases can be used to modify the genomes of hESCs and iPSCs13. ZFNs can be engineered to induce a double strand break (DSB) precisely at a predetermined position in the genome4. This DSB can be repaired by end-joining to drive targeted gene disruption, or via the homology-directed DNA repair pathway using an ectopically provided donor plasmid as a template. Depending on the donor design, this repair reaction can be used to generate large-scale deletions, gene disruptions, DNA addition4 or single nucleotide changes5.

Recent work on transcription activator-like effectors (TALEs) suggests6 suggests an alternative approach to the design of site-specific nucleases. Natural TALEs are transcription factors used by plant-pathogens to subvert host genome regulatory networks6. The DNA binding domain of TALEs is unusual: multiple ~34 amino acid units (”TALE repeats”) are arranged in tandem, their sequence nearly identical except for two highly variable amino acids that establish the base recognition specificity for each unit7, 8. Each individual domain determines the specificity of binding to one DNA base pair in the TALE recognition sequence and therefore four different repeat units are sufficient to specify a novel site7, 8. Nucleases based on such engineered TALE domains can target endogenous genes in transformed human cells9, 10. Here, we assess whether TALENs can be used to genetically engineer endogenous loci in hESCs and iPSCs.

We designed TALENs targeting PPP1R12C (the AAVS1 locus), OCT4, PITX3 genes at precisely the same positions as targeted earlier by ZFNs2. TALEN expression constructs and corresponding homology bearing donor plasmids were electroporated into hESCs (line WIBR#3)11 and iPSCs (line C1)12 (see FigureS 1, TableS 1, 2). Southern blot analysis was used to identify correctly targeted clones.

We targeted the PPP1R12C gene with a gene trap approach (expressing puromycin (Puro) from the endogenous gene; Figure 1A,B; Table 1) or with an autonomous selection cassette (Puro expressed from the PGK-promoter (Figure 1, Table 1; Figure S1, 2, 3). Targeting efficiency was high and comparable to that with ZFNs2 with 50% of the clones being targeted in one or both alleles carrying no randomly integrated transgenes (Figure 1B, Table 1; Figure S2). Similarly, a SA-Puro-eGFPeGFP transgene was highly expressed from this locus (Figure 1A; Figure S3A,B). Importantly, such targeted cells remained pluripotent based on analysis of marker expression and teratomas. Cells of all germ layers expressed eGFP indicating that TALEN as well as ZFN-mediated targeting of the PPP1R12C gene results in robust transgene expression in pluripotent as well as in differentiated cells (Figure S3C–E).

Figure 1
Genetic engineering of hESCs and iPSCs using TALENs
Table 1
Summary of targeting experiments using TALENs OCT 4

The OCT4 gene was targeted using three different donor plasmids resulting in expression of Puro and an OCT4 exon1-eGFP fusion protein under control of the endogenous OCT4 promoter. The first two donor plasmids were designed to integrate a splice acceptor-eGFP-2A-Puro cassette into the first intron of OCT4 whereas the third donor generated an in-frame fusion of exon 1 with the eGFP-2A-puromycin cassette (Figure S4). Targeting efficiency in ESCs and iPSCs was between 70% and 100% as determined by Southern blot analysis and DNA sequencing of single-cell-derived clones (Table 1, Figure S1,4).

We also targeted the first exon of the non-expressed PITX3 gene and found that ~6% of drug resistant clones carried the transgene solely at the PITX3 locus as evaluated by Southern blot analysis (Table 1, Figure S1, 5). Notably, in one clone the transgene had integrated into both alleles of the non-expressed PITX3 gene.

To target C’ terminus in the OCT4 gene, not previously targeted by ZFNs, we generated TALENs directed against sequences flanking the stop codon of the OCT4 gene using two donor plasmids: the last OCT4 codon was either fused in frame with a GFP-PGK-Puro construct or a with an eGFP preceded by a 2A sequence (2A-GFP-PGK-Puro; Figure 1C, Table 1). Following excision of the LoxP flanked PGK-Puro cassettes either a C-terminal OCT4-eGFP fusion protein or a separately translated eGFP proteins will be expressed under the control of the endogenous OCT4 gene13. Southern blot analysis showed that 2–10% of single cell derived hESC and hiPSC clones carried the transgene cassette at the OCT4 locus (Figure 1D, E; Table 1). Cre-mediated excision of the PGK-Puro cassette from OCT4-eGFP targeted hESCs resulted in nuclear eGFP fluorescence and from those targeted with OCT4-2A-eGFP -- in pan-cellular eGFP-fluorescence (Figure 1G). Fluorescence was higher in OCT4-2A-eGFP than in OCT4-eGFP targeted clones as determined by FACS analysis suggesting differential protein stabilities of the OCT4-eGFP fusion protein and eGFP (Figure S6). A gene trap vector fusing an eGFP-2A-Puro cassette with the last OCT4 codon had a 50% targeting efficiency (Figure 1C,F,G; Table 1; Figure S6) similar to that of gene trap-vectors designed to the first intron. As expected, eGFP expression became undetectable after differentiation into fibroblast-like cells (Figure S7) validating eGFP expression as a faithful reporter for OCT4 expression.

To illustrate the general utility of TALENs to generate such C-terminal fusion proteins, we designed TALENs to cut at the last coding exon of PITX3 and generated hESCs and iPSCs with an in-frame fusion of 2A-eGFP or eGFP. Targeting was highly efficient resulting in some clones carrying the transgene on both alleles (Figure S8; Table 1).

To assess the frequency of off-target modification not detected by Southern blot analysis we determined the binding specificity of the PPP1R12C TALENs using SELEX. When genotyping a panel of 19 maximal-likelihood potential off-target sites unintended cleavage was found only at low-frequency (See Figure S9, 10; Table S3, 4 and Supplemental material for detailed description). A strategy to minimize potential off-target events is to design TALENs to function as obligatory heterodimers14. As shown in Table 1, such heterodimeric nucleases in combination with the TALE DNA binding domain can yield high efficiency targeting of the PPP1R12C locus.

Individual TALE repeats can be joined to produce DNA binding domains capable of recognizing endogenous sequences in mammalian cells9, 10, 15. In the present work, we have built on the recent development of an efficient TALEN architecture9, and evaluated the utility of TALENs to drive targeted gene modifications in human ESCs and iPSCs. At all five genomic sites tested, we obtained clones carrying transgenes solely at the TALEN-specified locus at a frequency comparable to that observed with ZFNs2. As this approach couples a simple DNA recognition code with robust activity in human pluripotent stem cells, our data suggest that TALENs are a useful tool for investigator-specified targeting and genetic modification in human pluripotent cells with efficiencies similar to those we have previously reported for ZFNs.

Supplementary Material

Acknowledgments

We thank R. Alagappan, P. Xu, Sandra Cristea Stephen Lam and Anna Vincent for expert technical assistance. We thank Frank Soldner for helpful discussions on the manuscript. DH is a Merck Fellow of the Life Sciences Research Foundation. RJ was supported by US National Institutes of Health grants R37-CA084198, RO1-CA087869 and RO1-HD045022 and by a grant from HHMI. RJ is an adviser to Stemgen and a cofounder of Fate Therapeutics. GJC, LZ, YS, JCM, BZ, JMC, XM, SJH, EJR, PDG and FDU are full-time employees of Sangamo BioSciences, Inc..

Footnotes

Author contributions

DH, HW, and RJ designed the targeting experiments and wrote the manuscript. HW and DH generated donor plasmids. DH preformed targeting experiments. SK and CSL, HW assisted with Southern blot analysis. QG analyzed teratomas. JPC and DH performed FACS analysis of targeted cells. LZ and JM designed the TALENs, SH assembled the TALENs, GC and YS tested the TALENs, and BZ, JC, and XM performed the off-target analysis. DH, RJ, LZ, GC, JM, BZ, XM, and FDU analyzed the data. ER, PG, and FDU designed and supervised the design of the TALENs and contributed to writing the manuscript.

References

1. Zou J, et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell. 2009;5:97–110. [PMC free article] [PubMed]
2. Hockemeyer D, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol. 2009;27:851–857. [PMC free article] [PubMed]
3. Hockemeyer D, Jaenisch R. Gene Targeting in Human Pluripotent Cells; Cold Spring Harb Symp Quant Biol. [PubMed]
4. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11:636–646. [PubMed]
5. Soldner F, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011 in press. [PMC free article] [PubMed]
6. Boch J, Bonas U. Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu Rev Phytopathol. 48:419–436. [PubMed]
7. Boch J, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326:1509–1512. [PubMed]
8. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science. 2009;326:1501. [PubMed]
9. Miller JC, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 2011;29:143–148. [PubMed]
10. Cermak T, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res [PMC free article] [PubMed]
11. Lengner CJ, et al. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell. 141:872–883. [PubMed]
12. Hockemeyer D, et al. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell. 2008;3:346–353. [PMC free article] [PubMed]
13. Zwaka T, Thomson J. Homologous recombination in human embryonic stem cells. Nat Biotechnol. 2003;21:319–321. [PubMed]
14. Doyon Y, et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods. 8:74–79. [PubMed]
15. Zhang F, et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol. 2011;29:149–153. [PMC free article] [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...